Experience of successful use of axitinib in therapy of metastatic renal cell carcinoma after immunotargeted therapy
The therapeutic options for clear cell renal cell carcinoma have changed significantly in recent years. Back in 2018, clinical guidelines indicated that the standard of therapy for newly diagnosed metastatic renal cell cancer, regardless of the prognosis, was monotherapy with sunitinib or pazopanib....
Main Author: | A. A. Rumyantsev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/6592 |
Similar Items
-
Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01) -
Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01) -
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
by: Marco Stellato, et al.
Published: (2023-01-01) -
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
by: Yun Beom Sang, et al.
Published: (2022-12-01) -
Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)